NASDAQ · HALO
Healthcare · Biotechnology
$106.25
Up+$0.33 (+0.31%)
Updated Sep 16, 2026, 1:45 PM
SID Score
7.2/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
HALO closed at $106.25 after 20 trading sessions, up 1.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $108.14 | $108.14 | $106.14 | $106.25 | 1.06M |
| Sep 14, 2026 | $108.00 | $108.61 | $106.65 | $107.94 | 912.52K |
| Sep 11, 2026 | $107.96 | $108.225 | $106.34 | $107.20 | 861.58K |
| Sep 10, 2026 | $106.93 | $107.95 | $106.36 | $107.00 | 1.46M |
| Sep 9, 2026 | $107.67 | $108.79 | $106.62 | $107.39 | 1.75M |
| Sep 8, 2026 | $109.00 | $109.961 | $106.07 | $108.31 | 1.63M |
| Sep 4, 2026 | $109.91 | $111.149 | $109.00 | $110.19 | 1.01M |
| Sep 3, 2026 | $109.84 | $111.15 | $108.74 | $110.76 | 1.89M |
| Sep 2, 2026 | $105.84 | $109.76 | $105.48 | $109.66 | 1.62M |
| Sep 1, 2026 | $107.45 | $108.53 | $106.87 | $107.72 | 1.06M |
| Aug 31, 2026 | $104.48 | $106.94 | $103.47 | $106.49 | 1.28M |
| Aug 28, 2026 | $106.45 | $106.805 | $104.7001 | $105.35 | 1.68M |
| Aug 27, 2026 | $106.865 | $107.55 | $106.05 | $106.92 | 1.36M |
| Aug 26, 2026 | $109.32 | $109.66 | $107.00 | $107.06 | 1.71M |
| Aug 25, 2026 | $109.33 | $109.5499 | $107.55 | $109.32 | 1.6M |
| Aug 24, 2026 | $108.00 | $109.10 | $106.87 | $108.64 | 2.09M |
| Aug 21, 2026 | $106.20 | $108.49 | $105.91 | $108.17 | 1.15M |
| Aug 20, 2026 | $106.41 | $107.44 | $105.20 | $106.12 | 1.58M |
| Aug 19, 2026 | $106.39 | $107.96 | $105.50 | $107.62 | 2.54M |
| Aug 18, 2026 | $102.95 | $105.11 | $102.385 | $104.89 | 1.96M |
The latest Smart Investors Daily articles mentioning HALO.
HALO research
Company profile and research snapshot.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 7, 2026 | TD Cowen | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Halozyme Therapeutics, Inc. (HALO) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 3:45 PM EDTCompany ParticipantsHelen Torley - President,...
ChartMill · Sep 9, 2026
Halozyme Therapeutics (HALO) stock matches the high growth momentum screen with strong earnings, a technical rating of 9, and setup quality score of 8.
Yahoo · Sep 2, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Yahoo · Sep 2, 2026
Halozyme (NASDAQ:HALO) will participate in three healthcare investor conferences during September, giving management multiple opportunities to discuss its commercially validated ENHANZE platform and expanding portfolio of drug delivery technologies. Key Investor TakeawaysHalozyme (NASDAQ:HALO) management will participate in investor events hosted by Wells Fargo, Morgan Stanley and H.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HALO.
